Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures (2015 - 2016)
Ultragenyx Pharmaceutical (RARE) reported Gains from Sales and Divestitures of $52273.0 for Q4 2016, up 187.07% year-over-year from $18209.0 in Q1 2016, and up 187.07% on a QoQ basis from $18209.0 in Q4 2015.
Ultragenyx Pharmaceutical (RARE) has 2 years of Gains from Sales and Divestitures data on file, last reported at $52273.0 in Q4 2016.
- Quarterly Gains from Sales and Divestitures rose 187.07% year-over-year to $52273.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $52273.0 (up 187.07% YoY) and the FY2016 annual result came in at $52273.0, up 187.07% from the prior year.
- Gains from Sales and Divestitures advanced to $52273.0 in Q4 2016 per RARE's latest filing, from $18209.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $52273.0 in Q4 2016 and bottomed at $18209.0 in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 52,273.00 |
| Dec 31, 2016 | 52,273.00 |
| Dec 31, 2015 | 18,209.00 |
| Dec 31, 2015 | 18,209.00 |